Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00193115
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00193193
Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193401
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193362
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193232
Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00193388
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193349
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 346
- Registration Number
- NCT00193323
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00193245
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193375
© Copyright 2025. All Rights Reserved by MedPath